Dragon (RGMb) induces oxaliplatin resistance in colon cancer cells
Shi Ying
Huang Xiao-Xiao
Chen Guo-Bin
Wang Ying
Zhi Qiang
Liu Yuan-Sheng
Wu Xiao-Ling
Wang Li-Fen
Yang Bing
Xiao Chuan-Xing
Xing Hui-Qin
Ren Jian-Lin
Xia Yin
Guleng Bayasi
· 2016
期刊名称：
Oncotarget
2016 年
7 卷
30 期
摘要：
Colorectal cancer (CRC) is one of the most commonly diagnosed cancers and a major cause of cancer mortality. Chemotherapy resistance remains a major challenge for treating advanced CRC. Therefore, the identification of targets that induce drug resistance is a priority for the development of novel agents to overcome resistance. Dragon (also known as RGMb) is a member of the repulsive guidance molecule (RGM) family. We previously showed that Dragon expression increases with CRC progression in human patients. In the present study, we found that Dragon inhibited apoptosis and increased viability of CMT93 and HCT116 cells in the presence of oxaliplatin. Dragon induced resistance of xenograft tumor to oxaliplatinin treatment in mice. Mechanistically, Dragon inhibited oxaliplatin-induced JNK and p38 MAPK activation, and caspase-3 and PARP cleavages. Our results indicate that Dragon may be a novel target that induces drug resistance in CRC.
会员登录
